Cited by 339Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Immune checkpoint inhibitors in challenging populations

Open access

Johnson, Douglas B., Sullivan, Ryan J., Menzies, Alexander M.·2017·Cancer

Open this paper in CoChat — free account Open PDF

Abstract

Immune checkpoint inhibitors, including those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice have not qualified for or have been seriously underrepresented in immune checkpoint inhibitor clinical trials. Thus, a major gap in knowledge regarding the safety and efficacy of these agents persists in many populations, even after regulatory approval. To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical populations to assist both academic and community oncologists in treatment decision making. Specifically, this review focuses on the safety and activity of immune checkpoint inhibitors in patients with autoimmune disorders, organ transplant patients, patients with chronic viral infections, patients with ongoing immunosuppressant use, patients with organ dysfunction, pregnant patients, patients with brain metastases, patients at extremes of age, and patients with an impaired functional status. Cancer 2017;123:1904-1911. © 2017 American Cancer Society.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/cncr.30642

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398
Self-citation
Retracted
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725

Flagged first, then by citations

Show all 78 references

Research works printed but not linked: 1

Bethof A, 2015, Age on outcome and toxicity with anti–PD‐1/PD‐L1 therapy in patients with melanoma [abstract], Pigment Cell Melanoma Res, 28, 756

Sorted by citations

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747
Cutaneous melanoma
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque
Drobni, Z. D., Alvi, R. M., Taron, J., Zafar, A., Murphy, S., Rambarat, P. K., Mosarla, R. C., Lee, C., Zlotoff, D. A., Raghu, V. K., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049981 · Cited by 590
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D., Wu, X., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 538
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 457
The integration of inflammaging in age-related diseases
Fülöp, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 368
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Tison, A., Quéré, G., Misery, L., Funck‐Brentano, E., Danlos, F., Routier, É., Robert, C., Loriot, Y., Lambotte, O., Bonniaud, B., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41068 · Cited by 317
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247
Rheumatic immune-related adverse events from cancer immunotherapy
Calabrese, L. H., Calabrese, C. M., & Cappelli, L. C. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0074-9 · Cited by 237
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 231
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 183
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Warner, B. M., Baer, A. N., Lipson, E. J., Allen, C. T., Hinrichs, C. S., Rajan, A., Pelayo, E., Beach, M. E., Gulley, J. L., Madan, R. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0823 · Cited by 186
Cancer During Pregnancy: The Oncologist Overview
Hepner, A., Negrini, D., Hase, E. A., Exman, P., Testa, L., Trinconi, Â. F., Filassi, J. R., Francisco, R. P. V., Zugaib, M., O’Connor, T. L., et al. (2019) · World Journal of Oncology · doi:10.14740/wjon1177 · Cited by 157
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
Fisher, J., Zeitouni, N. C., Fan, W., & Samie, F. H. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.07.005 · Cited by 157
Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
Pérez-De-Lis, M., Retamozo, S., Flores-Chávez, A., Kostov, B., Pérez-Álvarez, R., Brito‐Zerón, P., & Ramos‐Casals, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1372421 · Cited by 151
Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress
Shields, M. D., Marin-Acevedo, J. A., & Pellini, B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321483 · Cited by 145
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
Sternberg, C. N., Loriot, Y., James, N. D., Choy, E., Castellano, D., López‐Ríos, F., Banna, G. L., Giorgi, U. D., Masini, C., Bamias, A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.015 · Cited by 133
Systemic treatment of HCC in special populations
Rimassa, L., Personeni, N., Czauderna, C., Foerster, F., & Galle, P. R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.026 · Cited by 131
Renal toxicities associated with pembrolizumab
Izzedine, H., Mathian, A., Champiat, S., Picard, C., Mateus, C., Routier, É., Varga, A., Malka, D., Leary, A. F., Michels, J., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy100 · Cited by 132
Immune Checkpoint Inhibitor Toxicity
Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 126
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Kaufman, H. L., Atkins, M. B., Subedi, P., Wu, J. J., Chambers, J. D., Mattingly, T. J., Campbell, J. D., Allen, J., Ferris, A. E., Schilsky, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0594-0 · Cited by 112
Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 102
Immune Checkpoint Molecules in Reproductive Immunology
Mikó, É., Meggyes, M., Doba, K., Barakonyi, A., & Szereday, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00846 · Cited by 99
Gynecologic cancer in pregnancy
Korenaga, T.-R. K., & Tewari, K. S. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.015 · Cited by 97
Managing cardiotoxicity associated with immune checkpoint inhibitors
Upadhrasta, S., Elias, H., Patel, K., & Zheng, L. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.02.004 · Cited by 83
Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials
Da, L., Teng, Y., Wang, N., Zaguirre, K., Liu, Y., Qi, Y., & Song, F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01671 · Cited by 84
Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature
Xu, W., Moor, R., Walpole, E. T., & Atkinson, V. G. (2019) · Melanoma Research · doi:10.1097/cmr.0000000000000586 · Cited by 79
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Jamal, S., Hudson, M., Fifi-Mah, A. V., & Ye, C. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.190084 · Cited by 80
Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience
Cacciotti, C., Choi, J. J., Alexandrescu, S., Zimmerman, M. A., Cooney, T. M., Chordas, C. A., Clymer, J. R., Chi, S. N., & Yeo, K. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03578-6 · Cited by 79
“How Much Time Do I Have?”: Communicating Prognosis in the Era of Exceptional Responders
LeBlanc, T. W., Temel, J. S., & Helft, P. R. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201211 · Cited by 74
Pathogenic, glycolytic PD-1+ B cells accumulate in the hypoxic RA joint
Floudas, A., Neto, N. G. B., Marzaioli, V., Murray, K., Moran, B., Monaghan, M. G., Low, C., Mullan, R. H., Rao, N. L., Krishna, V., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139032 · Cited by 73
Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer
Youn, B., Trikalinos, N. A., Mor, V., Wilson, I. B., & Dahabreh, I. J. (2020) · Cancer · doi:10.1002/cncr.32624 · Cited by 73
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Ready, N., Audigier-Valette, C., Goldman, J. W., Felip, E., Ciuleanu, T., Campelo, M. R. G., Jao, K., Barlési, F., Bordenave, S., Rijavec, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006127 · Cited by 77
Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
Hussain, N., Naeem, M., & Pinato, D. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1769398 · Cited by 69
Cardiotoxicity of Immune Therapy
Ganatra, S., Parikh, R. B., & Neilan, T. G. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.07.008 · Cited by 72
Immune checkpoint inhibitor administration during pregnancy: a case series
Andrikopoulou, A., Korakiti, A.-M., Apostolidou, K., Dimopoulos, M. A., & Zagouri, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100262 · Cited by 72
PD-1 checkpoint inhibition: Toxicities and management
Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 68
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Gambichler, T., Reuther, J., Scheel, C., & Becker, J. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001145 · Cited by 67
Nanomedicine-based immunotherapy for central nervous system disorders
Hanif, S., Muhammad, P., Chesworth, R., Rehman, F. U., Qian, R., Zheng, M., & Shi, B. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0429-z · Cited by 69
Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA)
Cao, R., Yuan, L., Ma, B., Wang, G., & Tian, Y. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01362-0 · Cited by 65
Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis
Su, Q., Zhang, X., Zhang, C., Hou, Y., Yao, Y., & Cao, B. (2018) · Journal of Immunology Research · doi:10.1155/2018/1027323 · Cited by 64
Keeping Expectations in Check With Immune Checkpoint Inhibitors
Temel, J. S., Gainor, J. F., Sullivan, R. J., & Greer, J. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2146 · Cited by 62
Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge
Galati, F., Magri, V., Arias-Cadena, P. A., Moffa, G., Rizzo, V., Pasculli, M., Botticelli, A., & Pediconi, F. (2023) · Diagnostics · doi:10.3390/diagnostics13040604 · Cited by 58
Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4+T cells
Wang, S., Chen, C., Li, M., Qian, J., Sun, F., Li, Y., Yu, M., Wang, M., Zang, X., Zhu, R., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1251-0 · Cited by 58
The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma
Jeyakumar, N., Etchegaray, M., Henry, J. T., Lelenwa, L. C., Zhao, B., Segura, A., & Buja, L. M. (2020) · Case Reports in Immunology · doi:10.1155/2020/5126717 · Cited by 57
Imaging findings of immune checkpoint inhibitor associated pancreatitis
Das, J. P., Postow, M. A., Friedman, C. F., Do, R. K., & Halpenny, D. F. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.109250 · Cited by 57
A light-driven dual-nanotransformer with deep tumor penetration for efficient chemo-immunotherapy
Peng, J., Chen, F., Liu, Y., Zhang, F., Cao, L., You, Q., Yang, D., Chang, Z., Ge, M., Li, L., et al. (2022) · Theranostics · doi:10.7150/thno.68756 · Cited by 58
Cancer and Pregnancy: A Comprehensive Review
Schwab, R. M., Anić, K., & Hasenburg, A. (2021) · Cancers · doi:10.3390/cancers13123048 · Cited by 56
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 52
Chelerythrine Chloride Downregulates β-Catenin and Inhibits Stem Cell Properties of Non-Small Cell Lung Carcinoma
Heng, W. S., & Cheah, S. (2020) · Molecules · doi:10.3390/molecules25010224 · Cited by 51
Dominant immune cells in pregnancy and pregnancy complications: T helper cells (TH1/TH2, TH17/Treg cells), NK cells, MDSCs, and the immune checkpoints
Esparvarinha, M., Madadi, S., Aslanian‐Kalkhoran, L., Nickho, H., Dolati, S., Pia, H., Danaii, S., Taghavi, S., & Yousefi, M. (2022) · Cell Biology International · doi:10.1002/cbin.11955 · Cited by 47
Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy
Wang, T., Suita, Y., Miriyala, S., Dean, J., Tapinos, N., & Shen, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040520 · Cited by 50
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51
Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
Guo, Z.-H., Khattak, S., Rauf, M. A., Ansari, M. A., Alomary, M. N., Razak, S., Yang, C., Wu, D., & Ji, X. (2023) · Molecules · doi:10.3390/molecules28031283 · Cited by 49
Ageing, immune fitness and cancer
Dolan, M., Libby, K. A., Ringel, A. E., van Galen, P., & McAllister, S. S. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00858-z · Cited by 55
Nano-drug delivery systems for T cell-based immunotherapy
Li, R. P., Chen, Z., Li, J., Dai, Z., & Yu, Y. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101621 · Cited by 48
Merkel cell polyomavirus and associated Merkel cell carcinoma
Yang, J. F., & You, J. (2021) · Tumour Virus Research · doi:10.1016/j.tvr.2021.200232 · Cited by 48
T lymphocyte-targeted immune checkpoint modulation in glioma
Kelly, W., Giles, A. J., & Gilbert, M. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000379 · Cited by 47
Immune Checkpoint Inhibitor Therapy in a Liver Transplant Recipient With Melanoma
Schvartsman, G., Perez, K., Sood, G., Katkhuda, R., & Tawbi, H. A. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0187 · Cited by 45
Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients
Zehou, O., Leibler, C., Arnault, J., Sayegh, J., Montaudié, H., Rémy, P., Glotz, D., Cordonnier, C., Martin, L., & Lebbé, C. (2018) · American Journal of Transplantation · doi:10.1111/ajt.15071 · Cited by 45
Immune-Related Adverse Events: A Case-Based Approach
Connolly, C. M., Bambhania, K., & Naidoo, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00530 · Cited by 46
Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
Li, L., Li, G., Rao, B., Dong, A.-H., Liang, W., Zhu, J., Qin, M.-P., Huang, W., Lu, J., Li, Z.-F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72649-5 · Cited by 46
Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice
Anderson, R., & Rapoport, B. L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00080 · Cited by 45
A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response
Liang, X., Li, L., Li, X., He, T., Gong, S., Zhu, S., Zhang, M., Wu, Q., & Gong, C. (2021) · Theranostics · doi:10.7150/thno.58173 · Cited by 46
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Schadendorf, D., Ascierto, P. A., Haanen, J. B. A. G., Espinosa, E., Демидов, Л. В., Garbe, C., Guida, M., Lorigan, P. C., Chiarion‐Sileni, V., Gogas, H. J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.014 · Cited by 43
Cancer Immunotherapies: Are They as Effective in the Elderly?
Poropatich, K., Fontanarosa, J., Samant, S., Sosman, J. A., & Zhang, B. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0479-1 · Cited by 42
Balancing Cancer Immunotherapy Efficacy and Toxicity
Johnson, D. B., Jakubovic, B. D., Sibaud, V., & Sise, M. E. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.06.028 · Cited by 46
Immunotherapy use outside clinical trial populations: never say never?
Rzeniewicz, K., Larkin, J., Menzies, A. M., & Turajlic, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.199 · Cited by 42
Preexisting autoimmune disease is a risk factor for immune-related adverse events: a meta-analysis
Yamaguchi, A., Saito, Y., Okamoto, K., Narumi, K., Furugen, A., Takekuma, Y., Sugawara, M., & Kobayashi, M. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06359-7 · Cited by 40
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
Age-Related Survival Differences in Patients With Inflammatory Bowel Disease–Associated Colorectal Cancer: A Population-Based Cohort Study
Bogach, J., Pond, G. R., Eskicioglu, C., & Seow, H. Y. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz088 · Cited by 38
Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model
Dow, E., Freimund, A. E., Smith, K. M., Hicks, R. J., Jurcevic, P., Shackleton, M. J., James, P. A., FELLOWES, A. P., Delatycki, M. B., Fawcett, S., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00429 · Cited by 37
Cutaneous immune-related adverse events to checkpoint inhibitors
Malviya, N., Tattersall, I., Leventhal, J. S., & Alloo, A. (2020) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2020.06.011 · Cited by 37
To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease
Pantuck, M. A., McDermott, D. F., & Drakaki, A. (2019) · Cancer · doi:10.1002/cncr.32326 · Cited by 37
SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)
Majem, M., García-Martínez, E., Martinez, M., Muñoz‐Couselo, E., Rodríguez‐Abreu, D., Álvarez, R., Arance, A. M., Berrocal, A., de la Cruz‐Merino, L., & Lopez-Martin, J. A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02273-x · Cited by 36
Treatment of keratinocyte carcinoma in elderly patients – a review of the current literature
Leus, A. J. G., Frie, M., Haisma, M. S., Terra, J. B., Plaat, B. E. C., Steenbakkers, R. J. H. M., Halmos, G. B., & Rácz, E. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16268 · Cited by 36
Advances on immune-related adverse events associated with immune checkpoint inhibitors
Fan, Y., Geng, Y., Shen, L., & Zhang, Z. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0735-3 · Cited by 35
The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
Chiang, C., Chiang, C., Sheng‐Kai, K., Hsia, Y. P., Lee, Y.-W., Wu, H., Chiang, C., Peng, C.-Y., Wei, J. C., Shiah, H., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac150 · Cited by 37
Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
Xia, Z., Zhang, J., Chen, W., Zhou, H., Du, D., Zhu, K., Chen, H., Meng, J., & Yang, J. (2023) · Infectious Diseases of Poverty · doi:10.1186/s40249-023-01128-6 · Cited by 34
Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 37
Relapsed Myasthenia Gravis after Nivolumab Treatment
Mitsune, A., Yanagisawa, S., Fukuhara, T., Miyauchi, E., Morita, M., Ono, M., Tojo, Y., & Ichinose, M. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9153-17 · Cited by 34
Immune Checkpoint Inhibitors in Transplantation—A Case Series and Comprehensive Review of Current Knowledge
Delyon, J., Zuber, J., Dorent, R., Poujol‐Robert, A., Péraldi, M., Anglicheau, D., & Lebbé, C. (2020) · Transplantation · doi:10.1097/tp.0000000000003292 · Cited by 34
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
Stege, H. M., Haist, M., Nikfarjam, U., Schultheis, M., Heinz, J., Pemler, S., Loquai, C., & Grabbe, S. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00840-3 · Cited by 35
Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients
Yang, W., Li, S., & Yang, Q. (2019) · Medicine · doi:10.1097/md.0000000000015731 · Cited by 33
The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?
Chen, H., Moussa, M., & Catálfamo, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01223 · Cited by 33
Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches
Motofei, I. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0643-4 · Cited by 30
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity
Shannon, V. R., Anderson, R., Blidner, A. G., Choi, J. N., Cooksley, T., Dougan, M. L., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05708-2 · Cited by 32
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma
Chen, H., Li, M., Ng, N., Yu, E., Bujarski, S. E., Yin, Z., Wen, M., Hekmati, T., Field, D., Wang, J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.17282 · Cited by 28
Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective
Li, W., Xu, X., & Jin, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17022 · Cited by 28
Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials
Riaz, I. B., Islam, M., Khan, A. M., Naqvi, S. A. A., Siddiqi, R. L., Khakwani, K. Z. R., Asghar, N., Ikram, W., Hussain, S. A., Singh, P. P., et al. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.03.042 · Cited by 28
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development
Rienzo, M., Skirecki, T., Monneret, G., & Timsit, J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2102477 · Cited by 28

Authors: Johnson, D. B., Sullivan, R. J., & Menzies, A. M.
Affiliations: Vanderbilt University Medical Center (US)
Massachusetts General Hospital (US)
The University of Sydney (AU)
Corresponding author: Johnson, Douglas B.
ORCID: Johnson, Douglas B.
Sullivan, Ryan J.
Menzies, Alexander M.
Venue: Cancer
Publisher: Wiley
Published: 2017-02-27
Volume: 123
Issue: 11
Pages: 1904-1911
ISSN: 0008-543X (ISSN-L)
1097-0142
DOI: 10.1002/cncr.30642
PMC: PMC5445005
OpenAlex: W2592187743
Cited by: 339
References: 78
Citations by year: 2026: 10 · 2025: 30 · 2024: 21 · 2023: 32 · 2022: 42 · 2021: 58 · 2020: 71 · 2019: 42 · 2018: 23 · 2017: 10
FWCI: 4.19
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Cancer (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K23 CA204726)
Cancer Institute NSW
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune checkpoint inhibitors, PD-1/PD-L1 pathway, underrepresented groups, autoimmune disease, organ transplant recipients, chronic viral infection, immunosuppressants, organ dysfunction, pregnancy, brain metastases, elderly patients, treatment safety, treatment efficacy
MeSH terms: Ipilimumab, Squamous Cell Carcinoma of Head and Neck, Nivolumab, Age Factors, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Female, Graft Rejection, Head and Neck Neoplasms, Humans, Immunosuppressive Agents, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pregnancy, Pregnancy Complications, Neoplastic, HIV Infections, Immunocompromised Host, Hepatitis B, Chronic, Hepatitis C, Chronic, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Transplant Recipients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immune checkpoint inhibitors in challenging populations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks